Compare Abeona Therapeutics Inc (ABEO) vs GameStop Corp. (GME) Price & Performance

ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.

The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.

GME trades at $18.57, down 1.2% with bearish technical signals from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant turnaround to profitability, achieving a 20.45% net income margin in 2025. Recent news highlights strategic shifts including potential partnership discussions with eBay instead of a full acquisition. Cash position strengthened to $4.77 billion following a $3.85 billion net cash inflow in 2025.

The outlook remains mixed with strong profitability improvements offset by bearish technical indicators and cautious analyst sentiment. Investment opportunity exists in the company's operational turnaround and cash-rich balance sheet, while risks include potential shareholder dilution from recent debt conversions and ongoing competitive pressures in the retail gaming sector.